SCHEMBL4494684

SCHEMBL4494684

CC(Oc1ccc(Br)cc1)N1CCOCC1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.48
TSHR P16473 3/20 0.48
HTT P42858 2/20 0.48
LMNA P02545 2/20 0.48
USP2 O75604 1/20 0.44
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
MGLL Q99685 1/20 0.42
ALDH1A1 P00352 3/20 0.42
KDM4E B2RXH2 1/20 0.42
ALOX12 P18054 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
TDP1 Q9NUW8 2/20 0.41
GLA P06280 1/20 0.41
MAPK1 P28482 1/20 0.41
ALOX15 P16050 1/20 0.40
HSD17B10 Q99714 1/20 0.40
CYP1A1 P04798 1/20 0.40
CYP1B1 Q16678 1/20 0.40
AAK1 Q2M2I8 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8164751 0.84 POLB (0.42) L3MBTL1TSHRLMNAKMT2AALDH1A1
SCHEMBL2634918 0.83 MEN1 (0.43) MEN1KMT2AALDH1A1TDP1MAPK1
SCHEMBL8927341 0.81 SMN1; SMN2 (0.43) L3MBTL1TSHRHTTLMNAMEN1
SCHEMBL2228938 0.79 ALDH1A1 (0.42) MEN1KMT2AALDH1A1ALOX15HSD17B10
SCHEMBL25306793 0.78 L3MBTL1 (0.64) L3MBTL1TSHRHTTUSP2ALDH1A1
SCHEMBL6531038 0.78 L3MBTL1 (0.44) L3MBTL1TSHRHTTLMNAUSP2
SCHEMBL8080901 0.78 MAPT (0.53) L3MBTL1HTTLMNAMEN1KMT2A
SCHEMBL25299662 0.78 TSHR (0.57) L3MBTL1TSHRUSP2MEN1KMT2A
SCHEMBL1927983 0.75 LTA4H (0.49) L3MBTL1TSHRMGLLALDH1A1KDM4E
SCHEMBL30206304 0.75 LTA4H (0.49) L3MBTL1TSHRMGLLALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7635695-B2 Antiinflammation agents AMGEN INC. (US) 2009-12-22 US disclosed
US-20070155777-A1 Antiinflammation agents AMGEN, INC. 2007-07-05 US disclosed
US-7199119-B2 Antiinflammation agents AMGEN INC. (US) 2007-04-03 US disclosed
EP-1556053-A4 ANTIINFLAMMATION AGENTS AMGEN INC (US) 2006-04-19 EP disclosed
EP-1556053-A1 ANTIINFLAMMATION AGENTS Amgen Inc. (US) 2005-07-27 EP disclosed
WO-2004041285-A1 ANTIINFLAMMATION AGENTS AMGEN INC. (US) 2004-05-21 WO disclosed
US-20040097485-A1 Antiinflammation agents TULARIK INC. 2004-05-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070155777-A1 Antiinflammation agents TNF, NFATC1, NFKBIA L3MBTL1 4524/4885TSHR 4127/4885HTT 3070/4885
US-20040097485-A1 Antiinflammation agents TNF, NFATC1, NFKBIA L3MBTL1 4524/4885TSHR 4127/4885HTT 3070/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.